T cells evolved over millions of years to protect the host from infections through the specific recognition and efficient killing of diseased cells. This concept has been widely used therapeutically over the last decade to treat infections and tumors via the adoptive transfer of naturally occurring, antigen-specific T cells. Recently, the engineering of T cells with antigen-specific TCRs has opened up new possibilities for generating more reliable and versatile “living drugs”. This involves introducing a transgene encoding a TCR of interest into autologous patient-derived lymphocytes ex vivo. The resulting TCR-engineered T cells are then reinfused into the patient, where they can eventually recognize and eliminate target cells. Our goal is to contribute to the accessibility of TCR therapy on a broad scale by constructing libraries of virus- and tumor-specific therapeutic TCRs, alongside developing T-cell manufacturing processes suitable for clinical application.